Monitoring anti‐CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction

Anti‐CD19 chimeric antigen receptor (CAR19) T cell therapy has produced impressive clinical efficacy in patients with relapsed or refractory B‐cell malignancies. As a living drug, monitoring the pharmacokinetics of CAR T cells in vivo is an important part of clinical work, which provides valuable in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jiali, Mao, Xia, Chen, Caixia, Long, Xiaolu, Chen, Liting, Zhou, Jianfeng, Zhu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087589/
https://www.ncbi.nlm.nih.gov/pubmed/35875964
http://dx.doi.org/10.1002/cyto.a.24676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087589/
https://www.ncbi.nlm.nih.gov/pubmed/35875964
http://dx.doi.org/10.1002/cyto.a.24676

Ejemplares similares